PPARG and metabolic dysfunction-associated steatotic liver disease: From a different perspective, it has been reported that HMGB1 may attenuate non-alcoholic fatty liver disease through activation of the liver x receptor–α-PPARγ pathway, promoting β-oxidation and relieving endoplasmic reticulum stress [34,35].